
Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5.
Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/
Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility.
Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range6-10, Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.
Diabetes is a complex and challenging condition that affects more than four million Canadians11 and requires around-the-clock management of glucose levels and decision‑making to manage safely.
"Small improvements can make a meaningful difference for people living with diabetes. Dexcom G7 15 Day reflects our ongoing commitment to simpler, more seamless diabetes management," said André Côté, Vice President and General Manager, Dexcom Canada.
New with Dexcom G7 15 Day:
Dexcom G7 features included with Dexcom G7 15 Day:
While authorized by Health Canada, Dexcom G7 15 Day is not yet available for purchase. André Côté shares, "Our focus is on ensuring that when the product becomes available, Canadians living with diabetes and their healthcare providers have the support, education, and experience they need from day one. We look forward to sharing more details as we move closer to availability."